AI in Oncology Market: Growth, Size, Share, and Trends

Report Code HIT 9231
Published in Dec, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

AI in Oncology Market by Player Type (Integrated Suite), Application (Drug Discovery, De Novo Drug Design, Diagnosis, Precision Medicine, Genomic), Technology (CNN, NLP), Cancer Type (Lung), End User (Hospitals, Pharma), & Region - Global Forecast to 2030

Overview

The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, reaching US$2.45 billion in 2024 and an impressive US$11.52 billion by 2030. This growth can be primarily attributed to rising investments in pharmaceutical and biotech companies to develop potential and advance cancer drugs to reduce the global cancer burden. AI streamlines drug discovery and development processes by offering predictive modeling, simulation, and advanced data analytics, making it easier to evaluate a drug’s safety and efficacy. This reduces drug discovery time and costs as it helps the user minimize the experimental work and optimize the clinical trial design.

AI in Oncology Market– Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the AI in Oncology Market

Asia Pacific

The Asia Pacific market is experiencing significant growth due to growing healthcare digitization, increasing awareness about early cancer detection, and the rising adoption of AI-driven diagnostic tools. Supportive government policies and a surge in R&D activities also contribute to market growth.

Advancements in data quality, machine learning algorithms, genomics, medical imaging, computing power, and clinical integration enhance AI models for cancer treatment and will significantly drive the market.

Emerging applications of AI in oncology, such as personalized treatment plans, drug development, and surgical planning and assistance, are expected to provide lucrative opportunities for market players.

The Asia Pacific AI in oncology market is projected to reach USD 2.74 billion by 2030, with a CAGR of 30.7%.

The limited availability of datasets remains a significant challenge in the AI in oncology market, mainly due to data privacy and protection regulations, limiting market growth opportunities.

Global AI in Oncology Market Dynamics

DRIVER: Growing prevalence of cancer

High incidences of cancer worldwide create urgency in finding effective and personalized diagnostic and treatment options. According to the International Agency for Research on Cancer (IARC), a cancer research agency of the World Health Organization (WHO), there were 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022. Lung cancer is the most common type of cancer, accounting for 12.4% of all diagnoses. Female breast cancer follows closely in second place, representing 11.6% of the total. Colorectal cancer ranks third, making up 9.6% of diagnoses. Prostate cancer accounts for 7.3%, while stomach cancer comprises 4.9% of all new cancer cases. IARC also projects that the number of new cancer cases will rise to 35 million by 2050, constituting a 77% increase. The rising cancer burden pushes for innovations to improve early detection, streamline care, and provide more targeted patient therapies. Al’s capacity to process large datasets, enhance early detection, tailor treatments, and optimize healthcare workflows is becoming increasingly critical. It can help tackle the challenges of cancer care by improving diagnostic precision, treatment effectiveness, and operational efficiency.

RESTRAINT: High initial costs

High initial investments are a major hindrance to the adoption of AI in the oncology market due to development, data acquisition, and regulatory approval charges. Companies operating in the oncology field incur many regulatory and data expenditures in addition to the enormous capital required for creating AI models. According to the Food and Drug Administration (FDA), regulatory processes can be costly. For instance, the cost of the 510(k) pre-market notification process is approximately USD 24,335, while the pre-market approval (PMA) process for class III devices costs up to USD 540,783. Regulatory costs for the De Novo Classification Request, which is necessary for new devices with no analog, amount to USD 162,235. These regulatory charges can be significant for small and medium AI solution providers, which already require substantial funding for research data collection and clinical trials. Data acquisition to train AI models is expensive and time-consuming, exceeding USD 1 million annually for a single dataset. Furthermore, companies must navigate differing national regulatory standards, which adds to the complexity and cost of their operations. The high upfront costs create a barrier to entry, making it difficult for smaller or early-stage companies to compete in the market.

 

OPPORTUNITY: Focus on personalized treatment plans

Cancer is a complex disease. AI is transforming oncology by allowing more personalized approaches to treatment. Analyzing individual patient characteristics, such as genetic profiles, tumor mutations, and clinical information, helps clinicians find tailored therapies that optimize treatment outcomes. This approach, particularly for treatments such as immunotherapy, aims to reduce side effects and improve patient responses. Compared to the traditional one-size-fits-all model, AI tools can predict how patients will respond to specific treatments. Many firms are increasingly adopting AI-related cancer care. For instance, in October 2024, Ataraxis AI (US) launched its availability for Ataraxis Breast, a prognostic and predictive tool for breast cancer that is 30% more accurate than standards at the moment. Similarly, GE Healthcare (US), in May 2024 at ESTRO 2024 Congress, announced its newest AI-based oncology solutions, such as Revolution RT Radiation Therapy CT Solution and the newly launched Intelligent Radiation Therapy (IRT) platform, which helps customers push boundaries for imaging precision, workflow efficiency, and individualized care. Earlier in June 2024, researchers at the University of Oxford developed an AI-based adaptive therapy approach for prostate cancer using deep reinforcement learning, which could potentially double relapse-free time.

CHALLENGES: Limited availability of datasets

The limited availability of datasets remains a significant challenge in the AI in oncology market, mainly due to data privacy and protection regulations. For instance, in the US, the Health Insurance Portability and Accountability Act (HIPAA) focuses on ensuring that health information remains confidential, secure, and accessible only to authorized individuals. Similarly, the General Data Protection Regulation (GDPR) provides broader protections for all personal data of EU residents, including health-related information. These regulations necessitate careful management of data privacy, and non-compliance can result in significant penalties of up to USD 21 million (EUR 20 million) or 4% of global revenue under GDPR and up to USD 2 million for severe violations of HIPAA. Other compliance challenges arise from the need to assess private requirements against increasing demands for high-quality datasets to train advanced AI models. This leads to fragmentation of data sources, inconsistent data formats, and labor-intensive data labeling, which impede the development of AI systems that can support precision oncology. To significantly advance AI applications in oncology treatment, it is crucial to address the limitations of these data.

Global AI in Oncology Market Ecosystem Analysis

The AI in oncology market ecosystem includes software providers, pharmaceutical and biotechnology companies, medical device/equipment companies, academic and research institutions, and government and regulatory agencies. The interaction among these players shapes the development, adoption, and advancement of AI-based technologies. Solution providers such as niche/point solution providers, integrated suite/platform providers, technology providers, and business process service providers in the market develop and cater AI-based software and services, such as diagnostic tools for imaging, predictive analytics for treatment planning, workflow automation to enhance efficiency and patient outcomes, and virtual assistants to provide reminders, or manage follow-ups.

AI in Oncology Market
 

The diagnosis and early detection segment accounted for the largest share of the AI in oncology market by application in 2023.

The early detection of cancer can significantly reduce mortality rates, as identifying cancer at an earlier stage improves survival and lowers treatment costs. In resource-poor settings, cancer is frequently diagnosed at an advanced stage, leading to lower survival rates and higher treatment costs. Early detection of cancer through AI-powered techniques, including radiomics and predictive analytics, allows for personalized treatment plans and better prognostic assessments, reducing mortality rates and improving overall survival. Improving access to diagnosis and ensuring timely treatment is crucial for minimizing delays in diagnosis. Currently, traditional machine learning techniques are more prevalent and support vector machines, as well as deep models such as Convolutional Neural Networks (CNN), which are increasingly deployed for earlier diagnoses in imaging diagnostics and molecular diagnostics. For instance, digital breast tomosynthesis combines AI to reduce recall rates and enhance detection. Similarly, low-dose CT scans, along with deep learning models, such as CNNs and Sybil, are useful for the prediction of lung cancer. Molecular tests such as lipid analysis for lung cancer and DeepGlioma for gliomas are also being combined with AI to refine early detection methods.

The solid tumor segment held the largest share of the AI in oncology market by cancer type in 2023.

In 2023, the solid tumor segment held the largest share of the AI in oncology market. Of all types of solid tumors, breast cancer ranked first due to its increasing prevalence worldwide. According to WHO, in 2022, breast cancer was the most common cancer among women in 157 countries. The statistics indicate there were 2.3 million diagnoses of breast cancer, along with 670,000 deaths. Similarly, the website breastcance.org reports that nearly 66% of breast cancer cases are locally diagnosed. The use of AI in early detection and diagnosis can help provide better survival rates and reduce treatment costs while improving the outcomes for patients. AI algorithms, such as deep learning and computer-aided detection (CAD), enhance the accuracy and speed of identifying tumors, improving early detection and treatment planning. Additionally, AI’s ability to analyze large datasets, including genomic and imaging information, supports personalized treatment approaches, driving its widespread adoption in breast cancer care. The integration of radiomics and machine learning models further refines tumor characterization and predicts treatment responses.

North America secured the largest share of the AI in Oncology Market in 2023.

In 2023, North America accounted for the largest share of the AI in oncology market. The region’s dominance can be primarily attributed to the significant presence of companies providing AI in oncology solutions, particularly in the US. Major US-based companies include GE Healthcare, ConcertAI, Oracle, NVIDIA Corporation, Predictive Oncology, PathAI, and CureMatrix. The North American AI in oncology market is further driven by ongoing advancements in machine learning and deep learning, rising accessibility of healthcare data, and increasing demand for precision medicine. Collaborations between tech firms and healthcare providers, along with established reimbursement policies, also enhance the integration of AI for cancer diagnostics, treatment planning, and precision medicine. For instance, in April 2024, Moffitt Cancer Center partnered with NVIDIA, Oracle, and Deloitte to reimagine cancer care using advanced AI and machine learning. In March 2024, NVIDIA collaborated with GE HealthCare to advance AI innovations with healthcare-specific foundation models powered by NVIDIA. Additionally, the region is home to several growing start-ups, such as CureMatch, Inc., Azra AI, and Triomics, that are driving innovation through AI-based oncology. These factors collectively position North America as a leading market in the field.

HIGHEST CAGR MARKET IN 2023
NORTH AMERICA FASTEST GROWING MARKET IN THE REGION
AI in Oncology Market

Recent Developments of AI in Oncology Market

  • In October 2024, GE HealthCare (US) launched its new cloud-first application, CareIntellect for Oncology. This application combines multi-modal patient data from various systems into a unified view, leveraging generative AI to summarize clinical notes and reports.
  • In September 2024, F. Hoffmann-La Roche Ltd. (Switzerland) collaborated with Qritive (Singapore) to enhance cancer diagnostics and treatment and the adoption of AI among pathologists. This collaboration will enable Qritive’s AI-powered solutions to be fully integrated with Roche’s Navify Digital Pathology platform, which will help pathologists diagnose cancer more accurately and efficiently.
  • In September 2024, Oracle (US) partnered with Imagene AI Ltd. (US) to introduce CanvOI, an advanced pan-cancer foundation model aimed at supporting innovative research and development in digital pathology and oncology.
  • In June 2024, ConcertAI (US) collaborated with NVIDIA Corporation (US) to enhance translational and clinical development solutions within its CARA AI platform. ConcertAI will leverage NVIDIA’s AI expertise and infrastructure, including the Meta Llama 3 NIM, to enhance oncology research and treatment through advanced LLM workloads.
  • In June 2024, Predictive Oncology (US) launched a unique 3D cell culture model to advance cancer drug discovery, offering more accurate in vivo testing and better predictions for clinical outcomes and drug candidate selection.
  • In May 2024, ConcertAI (US) launched CARA AI, a platform that integrates multi-modal data management, predictive AI, and generative AI to streamline and enhance healthcare processes. The platform supports life sciences and healthcare professionals in exploring multi-modal real-world data (RWD) while utilizing AI-driven workflows.

Key Market Players

KEY PLAYERS IN THE AI IN ONCOLOGY MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in AI in Oncology Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2030
Base Year Considered 2023
Forecast period 2024-2030
Forecast units Million/Billion (USD)
Segments covered Player Type, Application, Cancer Type, Technology, Deployment Model, and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, and Middle East Africa.

 

Key Questions Addressed by the Report

What are the major market players covered in the report?
Key players in the AI in oncology market are Siemens Healthineers (Germany), GE Healthcare (US), ConcertAI (US), Medtronic (Ireland), F. Hoffmann-La Roche Ltd (Switzerland), Oracle(US), NVIDIA Corporation(US), Koninklijke Philips N.V. (Netherlands), PathAI, Inc. (US) CureMetrix, Inc. (US), Mindpeak GmbH (Germany), Paige AI, Inc. (US), Predictive Oncology (US), and Exscientia (UK), among others.
Define AI in oncology market.
AI in oncology refers to using AI tools such as machine learning, natural language processing, and computer vision to analyze genomic data and large gene mutations unique to an individual’s cancer profile. These AI tools are adopted by various end users, including labs, research centers, hospitals, and biotechnology & pharmaceutical companies, to address the global cancer burden and the need for precision medicine in oncology.
Which region is expected to have the largest share of the AI in oncology market?
North America is expected to hold the largest share of the AI in oncology market during the forecast period.
Which end-user segments have been included in the AI in Oncology market report?
The report contains the following end-user segments:
  • Healthcare Providers
    • Hospitals & Clinics
    • Specialty Centers
    • Laboratories & Diagnostic Centers
    • Others
  • Pharmaceutical & Biotechnology Companies
  • Medical Device /Equipment Companies
  • Academic & Research Institutions
  • Government & Regulatory Agencies
  • Healthcare Payers
  • Others
How big is the global AI in Oncology market today?
The global AI in oncology market is estimated at USD 2.45 billion in 2024. It is projected to reach USD 11.52 billion by 2030, with a CAGR of 29.4%.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the AI in Oncology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table Of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
46
RESEARCH METHODOLOGY
53
EXECUTIVE SUMMARY
71
PREMIUM INSIGHTS
76
MARKET OVERVIEW
79
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing incidence of cancer disease
    - Growing need for early detection and diagnosis
    - Advancements in precision cancer treatment
    - Support from regulatory authorities
    - Increasing investments and funding
    RESTRAINTS
    - High initial costs
    - Data integrity and algorithm validation
    - Integration with existing systems
    OPPORTUNITIES
    - Radiomics and imaging analysis
    - Clinical trial optimization
    - Personalized treatment plans
    - Integration of multi-omics data
    CHALLENGES
    - Limited availability of datasets
    - Data privacy and security
  • 5.3 ECOSYSTEM ANALYSIS
  • 5.4 CASE STUDY ANALYSIS
    SIEMENS HEALTHINEERS IMPLEMENTED SYNGO.VIA RT IMAGE SUITE POWERED BY NVIDIA GPU-BASED SHERLOCK AI SUPERCOMPUTER
    AI IN ONCOLOGY FOR PERSONALIZED TREATMENT PLANNING
    PERSONALIZED OUTREACH FOR ONCOLOGISTS WITH TAKEDA'S AI SOLUTION
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY LANDSCAPE
    NORTH AMERICA
    EUROPE
    ASIA PACIFIC
    MIDDLE EAST & AFRICA
    LATIN AMERICA
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR AI IN ONCOLOGY
    JURISDICTION ANALYSIS
    MAJOR PATENTS IN AI IN ONCOLOGY MARKET
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Machine learning
    - Natural language processing
    - Computer vision
    COMPLEMENTARY TECHNOLOGIES
    - High-performance computing
    - Next-generation sequencing
    - Digital twins
    - Real-world evidence/real-world data
    ADJACENT TECHNOLOGIES
    - Cloud computing
    - Theranostics
    - Augmented and virtual reality
  • 5.10 INDUSTRY TRENDS
    SHIFT TOWARD PERSONALIZED ONCOLOGY
    EXPANSION OF AI-BASED CLINICAL TRIALS
  • 5.11 PRICING ANALYSIS
    INDICATIVE PRICING OF AI IN ONCOLOGY SOFTWARE, BY DEPLOYMENT MODEL
    AVERAGE SELLING PRICE OF AI IN ONCOLOGY PLATFORMS, BY REGION (2023)
  • 5.12 KEY CONFERENCES AND EVENTS, 2025
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS
    BUYING CRITERIA
  • 5.14 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.15 END USER ANALYSIS
    UNMET NEEDS
    END USER EXPECTATIONS
  • 5.16 INVESTMENT AND FUNDING SCENARIO
  • 5.17 IMPACT OF GENERATIVE AI ON AI IN ONCOLOGY MARKET
    KEY USE CASES
    CASE STUDIES OF GENERATIVE AI IMPLEMENTATION
    - Case Study 1: Accelerated drug discovery with Generative AI and streamlined workflows
    IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    - Pharmaceutical research and development market
    - Radiology and medical imaging market
    - Healthcare delivery systems market
    USER READINESS AND IMPACT ASSESSMENT
    - User readiness
    - Impact assessment
AI IN ONCOLOGY MARKET, BY TECHNOLOGY
120
  • 6.1 INTRODUCTION
  • 6.2 MACHINE LEARNING
    DEEP LEARNING
    - Need to streamline clinical workflows, reduce delays, and improve patient outcomes to drive market
    - Convolutional neural networks
    - Recurrent neural networks
    - Generative adversarial networks
    - Graph neural networks
    - Others
    SUPERVISED LEARNING
    - Surge in demand for accurate predictions and tailored treatments to drive market
    REINFORCEMENT LEARNING
    - Extensive use in drug discovery to drive market
    UNSUPERVISED LEARNING
    - Ability to perform complex tasks and uncover potential drug candidates to drive market
    OTHER MACHINE LEARNING TECHNOLOGIES
  • 6.3 NATURAL LANGUAGE PROCESSING
    EMERGING DEVELOPMENTS IN ONCOLOGY CARE TO DRIVE MARKET
  • 6.4 CONTEXT-AWARE PROCESSING AND COMPUTING
    ABILITY TO OPTIMIZE CLINICAL WORKFLOWS TO DRIVE MARKET
  • 6.5 COMPUTER VISION
    ELEVATED DEMAND FOR PRECISION MEDICINE TO DRIVE MARKET
  • 6.6 IMAGE ANALYSIS
    AUTOMATION OF COMPLEX IMAGING TASKS TO DRIVE MARKET
AI IN ONCOLOGY MARKET, BY APPLICATION
136
  • 7.1 INTRODUCTION
  • 7.2 DRUG DISCOVERY
    TARGET IDENTIFICATION & VALIDATION
    - Emphasis on avoiding last-stage failure in drug discovery to boost growth
    HIT IDENTIFICATION & PRIORITIZATION
    - Need for large-scale data analysis in HTS screening to drive adoption
    HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION
    - AI-driven lead generation to improve selectivity and binding mechanisms
    LEAD OPTIMIZATION
    - Need to accelerate make-design-test cycles and high possibility of clinical drug failure to spur market
    CANDIDATE SELECTION & VALIDATION
    - Candidate selection and validation to facilitate early drug discovery
  • 7.3 DRUG DEVELOPMENT
    PRECLINICAL TESTING
    - Need to identify risks and optimize candidates to boost growth
    PREDICTIVE MODELING FOR HUMAN TRIALS
    - Need for leveraging AI for accurate dose selection and safety assessments to boost growth
    CLINICAL TRIAL OPTIMIZATION
    - Need to enhance trial efficiency and outcomes with AI-driven insights to propel market
    ADAPTIVE TRIAL DESIGN & MONITORING
    - AI-driven adaptive trial design & monitoring help improve flexibility and success rates
  • 7.4 DIAGNOSIS & EARLY DETECTION
    IMAGING & RADIOLOGY
    - Mammography
    - Computed tomography (CT)
    - Magnetic resonance imaging (MRI)
    - Nuclear imaging
    - X-ray Imaging
    - Ultrasound
    - Other imaging modalities
    DIGITAL PATHOLOGY & HISTOPATHOLOGY
    - Focus on examining tissue samples to diagnose diseases to boost market
    LIQUID BIOPSY & BIOMARKER DETECTION
    - Advancements in non-invasive diagnostic technologies to propel growth
    GENETIC RISK PREDICTION
    - Increased awareness of people regarding hereditary cancer risk to encourage growth
  • 7.5 TREATMENT PLANNING & PERSONALIZATION
    PERSONALIZED TREATMENT PLANNING
    - Precision medicine & genomic analysis
    - Radiomics & radiogenomics
    - Predictive models for treatment response
    - Treatment recommendation systems
    RADIATION THERAPY
    - Need for effective tumor targeting to boost growth
    CHEMOTHERAPY
    - Focus on optimizing chemotherapy for targeted treatment and risk prediction to boost segmental growth
    IMMUNOTHERAPY
    - Use of immunotherapy for personalized and effective cancer care to boost growth
    TARGETED THERAPY
    - Combination & dose optimization
    - AI-guided drug delivery
    SURGICAL PLANNING & ASSISTANCE
    - Preoperative imaging & 3D modeling
    - Intraoperative guidance and robotics
    - Postoperative analysis & recovery
  • 7.6 PATIENT ENGAGEMENT & REMOTE MONITORING
    SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE
    - Symptom management & virtual assistance tools are beneficial for chronic disease management
    REMOTE PATIENT MONITORING
    - Need for AI-enhanced, real-time monitoring to augment growth
    PATIENT EDUCATION & EMPOWERMENT
    - Improved health literacy and engagement with AI-curated insights
  • 7.7 POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE
    RECURRENCE MONITORING
    - Need to improve cancer surveillance and accurate recurrence detection and prognosis to drive market
    LONG-TERM OUTCOME PREDICTION
    - Need for personalized care plans and chronic side-effect management to augment market
    MENTAL HEALTH & SUPPORT SYSTEMS
    - Prioritizing mental health support in cancer care to augment segmental growth
  • 7.8 DATA MANAGEMENT & ANALYTICS
    INTEGRATION OF GENOMIC AND CLINICAL DATA TO ACCELERATE DEMAND FOR AI-POWERED ANALYTICS
  • 7.9 OTHER APPLICATIONS
AI IN ONCOLOGY MARKET, BY CANCER TYPE
190
  • 8.1 INTRODUCTION
  • 8.2 SOLID TUMORS
    RISING PREVALENCE OF SOLID TUMORS TO BOOST NEED FOR AI-DRIVEN INNOVATIONS
    BREAST CANCER
    LUNG CANCER
    PROSTATE CANCER
    COLORECTAL CANCER
    BRAIN TUMOR
    OTHER SOLID TUMORS
  • 8.3 HEMATOLOGIC MALIGNANCIES
    RISING CASES OF BLOOD CANCER TO DRIVE MARKET
    LEUKEMIA
    LYMPHOMA
    MULTIPLE MYELOMA
    OTHER HEMATOLOGIC MALIGNANCIES
  • 8.4 OTHER CANCER TYPES
AI IN ONCOLOGY MARKET, BY END USER
206
  • 9.1 INTRODUCTION
  • 9.2 HEALTHCARE PROVIDERS
    NEED FOR IMPROVED DIAGNOSTIC ACCURACY, PERSONALIZED TREATMENT PLANNING, AND ENHANCED WORKFLOW EFFICIENCY TO BOOST MARKET
    HOSPITALS & CLINICS
    SPECIALTY CENTERS
    LABORATORIES & DIAGNOSTIC CENTERS
    OTHER HEALTHCARE PROVIDERS
  • 9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    NEED TO LEVERAGE AI FOR ACCELERATED ONCOLOGY DRUG DISCOVERY AND CLINICAL TRIALS TO BOOST GROWTH
  • 9.4 MEDICAL DEVICE/ EQUIPMENT COMPANIES
  • 9.5 ACADEMIC & RESEARCH INSTITUTIONS
  • 9.6 GOVERNMENT & REGULATORY AGENCIES
  • 9.7 HEALTHCARE PAYERS
  • 9.8 OTHER END USERS
AI IN ONCOLOGY MARKET, BY PLAYER TYPE
221
  • 10.1 INTRODUCTION
  • 10.2 NICHE/POINT SOLUTION PROVIDERS
    NICHE/POINT SOLUTION PROVIDERS ACCELERATE CANCER DRUG DISCOVERY AND DEVELOPMENT
  • 10.3 INTEGRATED SUITE/PLATFORM PROVIDERS
    INTEGRATED SUITE/PLATFORM PROVIDERS REDUCE NEED FOR MULTIPLE VENDORS AND ACCELERATE WORKFLOWS
  • 10.4 TECHNOLOGY PROVIDERS
    DEMAND FOR IMPROVED ONCOLOGY WORKFLOWS TO DRIVE MARKET
  • 10.5 BUSINESS PROCESS SERVICE PROVIDERS
    FOCUS ON OPTIMIZING NON-CLINICAL ONCOLOGY WORKFLOWS TO PROPEL MARKET GROWTH
AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL
228
  • 11.1 INTRODUCTION
  • 11.2 CLOUD-BASED MODEL
    NEED FOR ADVANCED CANCER RESEARCH AND TREATMENT TO BOOST USE OF CLOUD-BASED AI PLATFORMS
  • 11.3 ON-PREMISES MODEL
    NEED FOR ENHANCED DATA SECURITY AND COMPLIANCE TO PROPEL ADOPTION OF ON-PREMISES MODEL
  • 11.4 HYBRID MODEL
    NEED FOR ENHANCING SCALABILITY AND DATA SECURITY IN DIAGNOSTICS TO DRIVE USE OF HYBRID-BASED AI PLATFORMS
AI IN ONCOLOGY MARKET, BY REGION
234
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Rising number of clinical trials and drug discovery to drive market
    CANADA
    - Pharmaceutical giants advancing innovation and expanding access to clinical trials to fuel market
  • 12.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Advanced healthcare system and collaborative efforts to boost market
    UK
    - Government support for developing new AI platforms to drive innovation
    FRANCE
    - Growing R&D pipeline for oncology trials to drive market
    ITALY
    - Favorable regulatory scenarios to propel AI adoption in oncology
    SPAIN
    - Established network of research centers to propel market
    REST OF EUROPE
  • 12.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Increasing healthcare expenditure to drive demand for oncology solutions
    INDIA
    - Growing cancer burden and healthcare disparities to fuel adoption of AI in oncology
    JAPAN
    - Aging population and rising cancer rates to drive growth
    REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Rising cases of breast cancer to support market growth
    MEXICO
    - Use of AI in pediatric cancer treatment and chemotherapy complications to fuel market growth
    REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Growing cancer cases and increasing clinical trials to drive growth
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
476
  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 13.3 REVENUE ANALYSIS OF KEY PLAYERS
  • 13.4 MARKET SHARE ANALYSIS
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.8 BRAND/SOFTWARE COMPARISON
  • 13.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & ENHANCEMENTS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
496
  • 14.1 KEY PLAYERS
    NVIDIA CORPORATION
    - Business overview
    - Products/Solutions offered
    - Recent developments
    - MnM view
    GE HEALTHCARE
    - Business overview
    - Products/Solutions offered
    - Recent developments
    - MnM view
    SIEMENS HEALTHINEERS AG
    - Business overview
    - Products/Solutions offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD
    - Business overview
    - Products/Solutions offered
    - Recent developments
    - MnM view
    INSILICO MEDICINE
    - Business overview
    - Products/Solutions offered
    - Recent developments
    - MnM view
    CONCERTAI
    - Business overview
    - Products/Solutions offered
    - Recent developments
    MEDTRONIC
    - Business overview
    - Products/Solutions offered
    - Recent developments
    ORACLE
    - Business overview
    - Products/Solutions offered
    - Recent developments
    KONINKLIJKE PHILIPS N.V.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    PREDICTIVE ONCOLOGY
    - Business overview
    - Products/Solutions offered
    - Recent developments
    EXSCIENTIA
    - Business overview
    - Products/Solutions offered
    - Recent developments
    PATHAI, INC.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    CUREMETRIX, INC.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    MINDPEAK GMBH
    - Business overview
    - Products/Solutions offered
    - Recent developments
    PAIGE AI, INC.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    TEMPUS AI, INC.
    - Business overview
    - Products/Solutions offered
    - Recent developments
    IKTOS
    - Business overview
    - Products/Solutions offered
    - Recent developments
  • 14.2 OTHER PLAYERS
    AZRA AI
    CUREMATCH, INC.
    ONCOLENS
    TRIOMICS
    CLINAKOS
    PERTHERA, INC.
    CELLWORKS GROUP, INC.
    BIOMY, INC.
APPENDIX
568
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 USD EXCHANGE RATES, 2021–2023
  • TABLE 2 FACTOR ANALYSIS
  • TABLE 3 AI IN ONCOLOGY MARKET: RISK ASSESSMENT
  • TABLE 4 AI IN ONCOLOGY MARKET: IMPACT ANALYSIS
  • TABLE 5 AI IN ONCOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 6 IMPACT OF PORTER’S FIVE FORCES ON AI IN ONCOLOGY MARKET
  • TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 JURISDICTION ANALYSIS OF TOP PATENT APPLICANT COUNTRIES FOR AI IN ONCOLOGY
  • TABLE 13 AI IN ONCOLOGY MARKET: AVERAGE SELLING PRICE, BY REGION, 2023 (USD THOUSAND)
  • TABLE 14 AI IN ONCOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025
  • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TOP 3 END USERS (%)
  • TABLE 16 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • TABLE 17 UNMET NEEDS IN AI IN ONCOLOGY MARKET
  • TABLE 18 END USER EXPECTATIONS IN AI IN ONCOLOGY MARKET
  • TABLE 19 AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 20 AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 21 AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 22 AI IN ONCOLOGY MARKET FOR DEEP LEARNING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 23 AI IN ONCOLOGY MARKET FOR SUPERVISED LEARNING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 24 AI IN ONCOLOGY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 25 AI IN ONCOLOGY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 26 AI IN ONCOLOGY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 27 AI IN ONCOLOGY MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 28 AI IN ONCOLOGY MARKET FOR CONTEXT-AWARE PROCESSING AND COMPUTING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 29 AI IN ONCOLOGY MARKET FOR COMPUTER VISION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 30 AI IN ONCOLOGY MARKET FOR IMAGE ANALYSIS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 31 AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 32 AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 33 AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 34 AI IN ONCOLOGY MARKET FOR TARGET IDENTIFICATION & VALIDATION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 35 AI IN ONCOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 36 AI IN ONCOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 37 AI IN ONCOLOGY MARKET FOR LEAD OPTIMIZATION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 38 AI IN ONCOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 39 AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 40 AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 41 AI IN ONCOLOGY MARKET FOR PRECLINICAL TESTING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 42 AI IN ONCOLOGY MARKET FOR PREDICTIVE MODELING FOR HUMAN TRIALS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 43 AI IN ONCOLOGY MARKET FOR CLINICAL TRIAL OPTIMIZATION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 44 AI IN ONCOLOGY MARKET FOR ADAPTIVE TRIAL DESIGN & MONITORING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 45 AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 46 AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 47 AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 48 AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 49 AI IN ONCOLOGY MARKET FOR MAMMOGRAPHY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 50 AI IN ONCOLOGY MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 51 AI IN ONCOLOGY MARKET FOR MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2022–2030 (USD MILLION)
  • TABLE 52 AI IN ONCOLOGY MARKET FOR NUCLEAR IMAGING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 53 AI IN ONCOLOGY MARKET FOR X-RAY IMAGING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 54 AI IN ONCOLOGY MARKET FOR ULTRASOUND, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 55 AI IN ONCOLOGY MARKET FOR OTHER IMAGING MODALITIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 56 AI IN ONCOLOGY MARKET FOR DIGITAL PATHOLOGY & HISTOPATHOLOGY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 57 AI IN ONCOLOGY MARKET FOR LIQUID BIOPSY & BIOMARKER DETECTION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 58 AI IN ONCOLOGY MARKET FOR GENETIC RISK PREDICTION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 59 AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 60 AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 61 AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 62 AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 63 AI IN ONCOLOGY MARKET FOR PRECISION MEDICINE & GENOMIC ANALYSIS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 64 AI IN ONCOLOGY MARKET FOR RADIOMICS & RADIOGENOMICS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 65 AI IN ONCOLOGY MARKET FOR PREDICTIVE MODELS FOR TREATMENT RESPONSE, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 66 AI IN ONCOLOGY MARKET FOR TREATMENT RECOMMENDATION SYSTEMS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 67 AI IN ONCOLOGY MARKET FOR RADIATION THERAPY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 68 AI IN ONCOLOGY MARKET FOR CHEMOTHERAPY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 69 AI IN ONCOLOGY MARKET FOR IMMUNOTHERAPY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 70 AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 71 AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 72 AI IN ONCOLOGY MARKET FOR COMBINATION & DOSE OPTIMIZATION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 73 AI IN ONCOLOGY MARKET FOR AI-GUIDED DRUG DELIVERY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 74 AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 75 AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 76 AI IN ONCOLOGY MARKET FOR PREOPERATIVE IMAGING & 3D MODELING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 77 AI IN ONCOLOGY MARKET FOR INTRAOPERATIVE GUIDANCE & ROBOTICS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 78 AI IN ONCOLOGY MARKET FOR POSTOPERATIVE ANALYSIS & RECOVERY, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 79 AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 80 AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 81 AI IN ONCOLOGY MARKET FOR SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 82 AI IN ONCOLOGY MARKET FOR REMOTE PATIENT MONITORING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 83 AI IN ONCOLOGY MARKET FOR PATIENT EDUCATION & EMPOWERMENT, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 84 AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 85 AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 86 AI IN ONCOLOGY MARKET FOR RECURRENCE MONITORING, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 87 AI IN ONCOLOGY MARKET FOR LONG-TERM OUTCOME PREDICTION, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 88 AI IN ONCOLOGY MARKET FOR MENTAL HEALTH & SUPPORT SYSTEMS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 89 AI IN ONCOLOGY MARKET FOR DATA MANAGEMENT & ANALYTICS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 90 AI IN ONCOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 91 AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 92 AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 93 AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 94 AI IN ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 95 AI IN ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 96 AI IN ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 97 AI IN ONCOLOGY MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 98 AI IN ONCOLOGY MARKET FOR BRAIN TUMORS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 99 AI IN ONCOLOGY MARKET FOR OTHER SOLID TUMORS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 100 AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 101 AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 102 AI IN ONCOLOGY MARKET FOR LEUKEMIA, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 103 AI IN ONCOLOGY MARKET FOR LYMPHOMA, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 104 AI IN ONCOLOGY MARKET FOR MULTIPLE MYELOMA, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 105 AI IN ONCOLOGY MARKET FOR OTHER HEMATOLOGICAL MALIGNANCIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 106 AI IN ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 107 AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 108 AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 109 AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 110 AI IN ONCOLOGY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 111 AI IN ONCOLOGY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 112 AI IN ONCOLOGY MARKET FOR LABORATORIES & DIAGNOSTIC CENTERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 113 AI IN ONCOLOGY MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 114 AI IN ONCOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 115 AI IN ONCOLOGY MARKET FOR MEDICAL DEVICE/ EQUIPMENT COMPANIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 116 AI IN ONCOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 117 AI IN ONCOLOGY MARKET FOR GOVERNMENT & REGULATORY AGENCIES, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 118 AI IN ONCOLOGY MARKET FOR HEALTHCARE PAYERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 119 AI IN ONCOLOGY MARKET FOR OTHER END USERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 120 AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 121 AI IN ONCOLOGY MARKET FOR NICHE/POINT SOLUTION PROVIDERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 122 AI IN ONCOLOGY MARKET FOR INTEGRATED SUITE/PLATFORM PROVIDERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 123 AI IN ONCOLOGY MARKET FOR TECHNOLOGY PROVIDERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 124 AI IN ONCOLOGY MARKET FOR BUSINESS PROCESS SERVICE PROVIDERS, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 125 AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 126 AI IN ONCOLOGY MARKET FOR CLOUD-BASED MODEL, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 127 AI IN ONCOLOGY MARKET FOR ON-PREMISES MODEL, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 128 AI IN ONCOLOGY MARKET FOR HYBRID MODEL, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 129 AI IN ONCOLOGY MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 130 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 131 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 132 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 133 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 134 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 135 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 136 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 137 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 138 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 139 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 140 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 141 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 142 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 143 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 144 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 145 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 146 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 147 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 148 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 149 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 150 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 151 US: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 152 US: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 153 US: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 154 US: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 155 US: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 156 US: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 157 US: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 158 US: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 159 US: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 160 US: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 161 US: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 162 US: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 163 US: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 164 US: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 165 US: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 166 US: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 167 US: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 168 US: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 169 US: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 170 US: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 171 CANADA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 172 CANADA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 173 CANADA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 174 CANADA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 175 CANADA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 176 CANADA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 177 CANADA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 178 CANADA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 179 CANADA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 180 CANADA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 181 CANADA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 182 CANADA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 183 CANADA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 184 CANADA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 185 CANADA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 186 CANADA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 187 CANADA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 188 CANADA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 189 CANADA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 190 CANADA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 191 EUROPE: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 192 EUROPE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 193 EUROPE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 194 EUROPE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 195 EUROPE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 196 EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 197 EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 198 EUROPE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 199 EUROPE: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 200 EUROPE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 201 EUROPE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 202 EUROPE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 203 EUROPE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 204 EUROPE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 205 EUROPE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 206 EUROPE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 207 EUROPE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 208 EUROPE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 209 EUROPE: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 210 EUROPE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 211 EUROPE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 212 GERMANY: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 213 GERMANY: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 214 GERMANY: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 215 GERMANY: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 216 GERMANY: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 217 GERMANY: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 218 GERMANY: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 219 GERMANY: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 220 GERMANY: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 221 GERMANY: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 222 GERMANY: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 223 GERMANY: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 224 GERMANY: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 225 GERMANY: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 226 GERMANY: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 227 GERMANY: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 228 GERMANY: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 229 GERMANY: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 230 GERMANY: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 231 GERMANY: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 232 UK: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 233 UK: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 234 UK: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 235 UK: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 236 UK: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 237 UK: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 238 UK: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 239 UK: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 240 UK: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 241 UK: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 242 UK: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 243 UK: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 244 UK: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 245 UK: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 246 UK: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 247 UK: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 248 UK: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 249 UK: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 250 UK: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 251 UK: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 252 FRANCE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 253 FRANCE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 254 FRANCE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 255 FRANCE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 256 FRANCE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 257 FRANCE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 258 FRANCE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 259 FRANCE: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 260 FRANCE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 261 FRANCE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 262 FRANCE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 263 FRANCE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 264 FRANCE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 265 FRANCE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 266 FRANCE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 267 FRANCE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 268 FRANCE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 269 FRANCE: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 270 FRANCE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 271 FRANCE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 272 ITALY: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 273 ITALY: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 274 ITALY: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 275 ITALY: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 276 ITALY: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 277 ITALY: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 278 ITALY: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 279 ITALY: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 280 ITALY: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 281 ITALY: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 282 ITALY: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 283 ITALY: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 284 ITALY: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 285 ITALY: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 286 ITALY: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 287 ITALY: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 288 ITALY: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 289 ITALY: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 290 ITALY: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 291 ITALY: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 292 SPAIN: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 293 SPAIN: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 294 SPAIN: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 295 SPAIN: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 296 SPAIN: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 297 SPAIN: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 298 SPAIN: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 299 SPAIN: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 300 SPAIN: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 301 SPAIN: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 302 SPAIN: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 303 SPAIN: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 304 SPAIN: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 305 SPAIN: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 306 SPAIN: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 307 SPAIN: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 308 SPAIN: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 309 SPAIN: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 310 SPAIN: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 311 SPAIN: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 312 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 313 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 314 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 315 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 316 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 317 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 318 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 319 REST OF EUROPE AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 320 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 321 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 322 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 323 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 324 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 325 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 326 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 327 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 328 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 329 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 330 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 331 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 332 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 333 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 334 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 335 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 336 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 337 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 338 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 339 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 340 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 341 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 342 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 343 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 344 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 345 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 346 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 347 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 348 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 349 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 350 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 351 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 352 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 353 CHINA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 354 CHINA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 355 CHINA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 356 CHINA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 357 CHINA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 358 CHINA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 359 CHINA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 360 CHINA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 361 CHINA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 362 CHINA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 363 CHINA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 364 CHINA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 365 CHINA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 366 CHINA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 367 CHINA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 368 CHINA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 369 CHINA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 370 CHINA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 371 CHINA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 372 CHINA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 373 INDIA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 374 INDIA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 375 INDIA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 376 INDIA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 377 INDIA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 378 INDIA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 379 INDIA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 380 INDIA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 381 INDIA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 382 INDIA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 383 INDIA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 384 INDIA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 385 INDIA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 386 INDIA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 387 INDIA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 388 INDIA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 389 INDIA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 390 INDIA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 391 INDIA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 392 INDIA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 393 JAPAN: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 394 JAPAN: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 395 JAPAN: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 396 JAPAN: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 397 JAPAN: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 398 JAPAN: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 399 JAPAN: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 400 JAPAN: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)S
  • TABLE 401 JAPAN: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 402 JAPAN: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 403 JAPAN: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 404 JAPAN: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 405 JAPAN: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 406 JAPAN: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 407 JAPAN: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 408 JAPAN: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 409 JAPAN: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 410 JAPAN: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 411 JAPAN: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 412 JAPAN: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 413 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 414 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 415 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 416 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 417 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 418 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 419 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 420 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 421 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 422 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 423 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 424 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 425 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 426 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 427 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 428 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 429 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 430 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 431 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 432 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 433 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 434 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 435 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 436 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 437 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 438 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 439 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 440 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 441 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 442 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 443 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 444 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 445 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 446 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 447 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 448 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 449 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 450 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 451 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 452 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 453 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 454 BRAZIL: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 455 BRAZIL: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 456 BRAZIL: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 457 BRAZIL: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 458 BRAZIL: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 459 BRAZIL: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 460 BRAZIL: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 461 BRAZIL: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 462 BRAZIL: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 463 BRAZIL: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 464 BRAZIL: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 465 BRAZIL: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 466 BRAZIL: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 467 BRAZIL: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 468 BRAZIL: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 469 BRAZIL: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 470 BRAZIL: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 471 BRAZIL: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 472 BRAZIL: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 473 BRAZIL: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 474 MEXICO: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 475 MEXICO: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 476 MEXICO: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 477 MEXICO: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 478 MEXICO: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 479 MEXICO: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 480 MEXICO: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 481 MEXICO: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 482 MEXICO: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 483 MEXICO: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 484 MEXICO: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 485 MEXICO: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 486 MEXICO: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 487 MEXICO: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 488 MEXICO: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 489 MEXICO: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 490 MEXICO: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 491 MEXICO: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 492 MEXICO: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 493 MEXICO: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 494 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 495 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 496 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 497 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 498 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 499 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 500 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 501 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 502 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 503 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 504 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 505 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 506 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 507 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 508 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 509 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 510 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 511 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 512 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 513 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 514 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 515 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 516 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 517 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 518 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 519 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 520 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 521 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 522 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 523 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 524 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 525 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 526 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 527 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 528 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 529 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 530 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 531 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 532 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 533 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 534 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 535 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 536 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 537 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 538 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 539 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 540 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 541 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 542 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 543 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 544 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 545 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 546 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 547 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 548 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 549 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 550 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 551 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 552 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 553 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 554 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 555 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)
  • TABLE 556 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 557 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 558 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
  • TABLE 559 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 560 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 561 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 562 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 563 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 564 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 565 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 566 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 567 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 568 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 569 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)
  • TABLE 570 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 571 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 572 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 573 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 574 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION)
  • TABLE 575 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • TABLE 576 AI IN ONCOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 577 AI IN ONCOLOGY MARKET: PLAYER TYPE FOOTPRINT
  • TABLE 578 AI IN ONCOLOGY MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 579 AI IN ONCOLOGY MARKET: DEPLOYMENT MODEL FOOTPRINT
  • TABLE 580 AI IN ONCOLOGY MARKET: REGION FOOTPRINT
  • TABLE 581 AI IN ONCOLOGY MARKET: LIST OF KEY STARTUPS/SMES
  • TABLE 582 AI IN ONCOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 583 AI IN ONCOLOGY MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021–NOVEMBER 2024
  • TABLE 584 AI IN ONCOLOGY MARKET: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 585 AI IN ONCOLOGY MARKET: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 586 AI IN ONCOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024
  • TABLE 587 NVIDIA CORPORATION: COMPANY OVERVIEW
  • TABLE 588 NVIDIA CORPORATION: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 589 NVIDIA CORPORATION: DEALS, JANUARY 2021− NOVEMBER 2024
  • TABLE 590 GE HEALTHCARE: COMPANY OVERVIEW
  • TABLE 591 GE HEALTHCARE: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 592 GE HEALTHCARE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021− NOVEMBER 2024
  • TABLE 593 GE HEALTHCARE: DEALS, JANUARY 2021− NOVEMBER 2024
  • TABLE 594 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 595 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 596 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 597 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 598 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021−NOVEMBER 2024
  • TABLE 599 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 600 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 601 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 602 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 603 INSILICO MEDICINE: COMPANY OVERVIEW
  • TABLE 604 INSILICO MEDICINE: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 605 INSILICO MEDICINE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021– NOVEMBER 2024
  • TABLE 606 INSILICO MEDICINE: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 607 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024
  • TABLE 608 CONCERTAI: COMPANY OVERVIEW
  • TABLE 609 CONCERTAI: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 610 CONCERTAI: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 611 CONCERTAI: DEALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 612 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 613 MEDTRONIC: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 614 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 615 MEDTRONIC: DEALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 616 ORACLE: COMPANY OVERVIEW
  • TABLE 617 ORACLE: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 618 ORACLE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 619 ORACLE: DEALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 620 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 621 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 622 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 623 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW
  • TABLE 624 PREDICTIVE ONCOLOGY: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 625 PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 626 PREDICTIVE ONCOLOGY: DEALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 627 EXSCIENTIA: COMPANY OVERVIEW
  • TABLE 628 EXSCIENTIA: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 629 EXSCIENTIA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 630 EXSCIENTIA: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 631 EXSCIENTIA: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 632 EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024
  • TABLE 633 PATHAI, INC.: COMPANY OVERVIEW
  • TABLE 634 PATHAI, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 635 PATHAI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 636 PATHAI, INC.: DEALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 637 CUREMETRIX, INC.: COMPANY OVERVIEW
  • TABLE 638 CUREMETRIX, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 639 CUREMETRIX, INC.: OTHER DEVELOPMENTS, JANUARY 2021−NOVEMBER 2024
  • TABLE 640 MINDPEAK GMBH: COMPANY OVERVIEW
  • TABLE 641 MINDPEAK GMBH: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 642 MINDPEAK GMBH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021− NOVEMBER 2024
  • TABLE 643 MINDPEAK GMBH: DEALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 644 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021−NOVEMBER 2024
  • TABLE 645 PAIGE AI, INC.: COMPANY OVERVIEW
  • TABLE 646 PAIGE AI, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 647 PAIGE AI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 648 PAIGE AI, INC.: DEALS, JANUARY 2021−NOVEMBER 2024
  • TABLE 649 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021−NOVEMBER 2024
  • TABLE 650 TEMPUS AI, INC.: COMPANY OVERVIEW
  • TABLE 651 TEMPUS AI, INC.: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 652 TEMPUS AI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 653 TEMPUS AI, INC.: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 654 TEMPUS AI, INC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 655 TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024
  • TABLE 656 IKTOS: COMPANY OVERVIEW
  • TABLE 657 IKTOS: PRODUCTS/SOLUTIONS OFFERED
  • TABLE 658 IKTOS: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 659 IKTOS: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION
  • FIGURE 5 AI IN ONCOLOGY MARKET: REVENUE ESTIMATION APPROACH
  • FIGURE 6 BOTTOM-UP APPROACH (2A): END USER SPENDING ON AI IN ONCOLOGY
  • FIGURE 7 BOTTOM-UP APPROACH (2B): END USER SPENDING ON AI IN ONCOLOGY
  • FIGURE 8 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2030)
  • FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 10 TOP-DOWN APPROACH
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 INTEGRATED SUITE/PLATFORM PROVIDERS SEGMENT TO LEAD MARKET BY 2030
  • FIGURE 13 DIAGNOSIS & EARLY DETECTION SEGMENT TO ACCOUNT FOR LARGEST SHARE BY 2030
  • FIGURE 14 SOLID TUMORS SEGMENT TO LEAD MARKET BY 2030
  • FIGURE 15 AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2024 VS. 2030 (USD MILLION)
  • FIGURE 16 MACHINE LEARNING SEGMENT TO ACCOUNT FOR LARGEST SHARE BY 2030
  • FIGURE 17 HEALTHCARE PROVIDERS SEGMENT TO LEAD MARKET BY 2030
  • FIGURE 18 ASIA PACIFIC TO ACHIEVE HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 19 FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET
  • FIGURE 20 NORTH AMERICA TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 21 CLOUD-BASED MODEL AND US ACCOUNTED FOR SIGNIFICANT SHARE IN 2023
  • FIGURE 22 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 23 GROWTH RATES OF EMERGING MARKETS TO BE HIGHER THAN THOSE OF DEVELOPED MARKETS DURING FORECAST PERIOD
  • FIGURE 24 AI IN ONCOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 NEW CANCER CASES AND CANCER DEATHS IN US, 2024
  • FIGURE 26 FUNDING RECEIVED BY AI IN ONCOLOGY COMPANIES IN 2024
  • FIGURE 27 NUMBER OF CANCER PUBLICATIONS OVER TIME (WITH OR WITHOUT AI AND RADIOMICS)
  • FIGURE 28 DISTRIBUTION OF CANCER CLINICAL TRIALS, BY PHASE
  • FIGURE 29 AI IN ONCOLOGY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 30 AI IN ONCOLOGY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 31 PORTER’S FIVE FORCES ANALYSIS OF AI IN ONCOLOGY MARKET
  • FIGURE 32 PATENT PUBLICATION TRENDS IN AI IN ONCOLOGY MARKET, 2015–2024
  • FIGURE 33 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR “AI IN ONCOLOGY” PATENTS (JANUARY 2015–SEPTEMBER 2024)
  • FIGURE 34 MAJOR PATENTS IN AI IN ONCOLOGY MARKET (JANUARY 2015– SEPTEMBER 2024)
  • FIGURE 35 AI IN ONCOLOGY MARKET: AVERAGE SELLING PRICE, BY REGION, 2023
  • FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TOP 3 END USERS
  • FIGURE 37 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • FIGURE 38 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 39 INVESTMENT AND FUNDING SCENARIO IN AI IN ONCOLOGY MARKET
  • FIGURE 40 POTENTIAL OF GENERATIVE AI IN AI IN ONCOLOGY MARKET
  • FIGURE 41 IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 42 NEW CANCER CASES IN US, BY CANCER TYPE, 2024
  • FIGURE 43 PERCENTAGE ESTIMATION OF HEMATOLOGIC MALIGNANCY CASES IN US, BY TYPE, 2024
  • FIGURE 44 AI IN ONCOLOGY MARKET, BY REGION, 2023 (USD MILLION)
  • FIGURE 45 NORTH AMERICA: AI IN ONCOLOGY MARKET SNAPSHOT
  • FIGURE 46 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION, 2021 VS. 2022
  • FIGURE 47 DISTRIBUTION OF CANCER CASES, BY CANCER TYPE, 2024 (MALES)
  • FIGURE 48 DISTRIBUTION OF CANCER CASES, BY CANCER TYPE, 2024 (FEMALES)
  • FIGURE 49 INCIDENCE OF CANCER IN MALES IN ITALY, BY CANCER TYPE, 2022
  • FIGURE 50 INCIDENCE OF CANCER IN FEMALES IN ITALY, BY CANCER TYPE, 2022
  • FIGURE 51 ASIA PACIFIC: AI IN ONCOLOGY MARKET SNAPSHOT
  • FIGURE 52 REVENUE ANALYSIS OF TOP 5 PLAYERS, 2019–2023 (USD BILLION)
  • FIGURE 53 AI IN ONCOLOGY MARKET SHARE ANALYSIS, 2023
  • FIGURE 54 AI IN ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 55 AI IN ONCOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 56 AI IN ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 57 COMPANY VALUATION OF KEY PLAYERS, 2024
  • FIGURE 58 EV/EBITDA OF KEY PLAYERS, 2024
  • FIGURE 59 AI IN ONCOLOGY MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 60 NVIDIA CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 61 GE HEALTHCARE: COMPANY SNAPSHOT (2023)
  • FIGURE 62 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 63 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
  • FIGURE 64 MEDTRONIC: COMPANY SNAPSHOT (2023)
  • FIGURE 65 ORACLE: COMPANY SNAPSHOT (2023)
  • FIGURE 66 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 67 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT (2023)
  • FIGURE 68 EXSCIENTIA: COMPANY SNAPSHOT

The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

Secondary Research

This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

Primary Research

In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

Breakdown of Primary Participants:

AI in Oncology Market

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
AI in Oncology Market

Data Triangulation

After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

  • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
  • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
  • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

Stakeholders

  • Clinical/Physician Centers
  • AI Providers
  • Clinical Research Organizations
  • Pharmaceutical/Biopharmaceutical Companies
  • Research and Development (R&D) Companies
  • Business Research and Consulting Service Providers
  • Medical Research Laboratories
  • Academic Medical Centers/Universities/Hospitals
  • Government Agencies
  • Regulatory Agencies
  • Clinical Researchers
  • Clinical Research Organizations
  • Accountable Care Organizations
  • Investors and Venture Capitalists

Report Objectives

  • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
  • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
  • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
  • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
  • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
  • To profile the key players and comprehensively analyze their market sizes and core competencies
  • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

Previous Versions of this Report

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in AI in Oncology Market

DMCA.com Protection Status